The demand for GLP-1 agonists, including Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for cardiovascular indication for Wegovy and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the promise of these treatments.
The Forbes report adds that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
A study published in the Journal of ...
